Standard BioTools Inc. Announces Incentive Grants Under Nasdaq Listing Rule 5635(c)(4)
Get instant alerts when news breaks on your stocks. Claim your one week free trial for StreetInsider Premium here.
SOUTH SAN FRANCISCO, Calif., April 05, 2022 (GLOBE NEWSWIRE) — Standard BioTools Inc. (f/k/a Fluidigm Corporation) (Nasdaq:FLDM) today announced, as required by stock market rules of the Nasdaq Stock Incentive Rewards for New Executives Michael Egholm, the company’s new president, chief executive officer and member of the company’s board of directors, and Hanjoon (Alex) Kim, the company’s new chief company operations, and a new employee, Ardalan (Alex ) Arfaei, the new senior vice president of corporate development.
Pursuant to Nasdaq listing rule 5635(c)(4), Standard BioTools’ Compensation Committee of its Board of Directors, which is comprised entirely of independent directors, approved the grant of the stock awards. following to Dr. Egholm and MM. Kim and Arfaei, each as a material incentive for Dr. Egholm and MM. Kim and Arfaei entering employment with Standard BioTools, April 4, 2022: a grant of non-statutory stock options to purchase 4,529,773 common shares and a grant of 786,049 restricted stock units (RSU) to Dr. Egholm; a grant of non-statutory stock options to purchase 1,617,775 ordinary shares and a grant of 280,732 RSU for Mr. Kim; and a grant of non-statutory stock options to purchase 1,294,221 common shares and a grant of 224,585 PSUs to Mr. Arfaei. Dr. Egholm, Mr. Kim and Mr. Arfaei both started working at Standard BioTools on April 4, 2022.
Each stock option grant has a term of 10 years and an exercise price per share equal to $3.99, the closing price of Standard BioTools common stock as listed on the Nasdaq Global Select Market on the grant date. Subject to the beneficiary’s continuous service up to each such relevant date, twenty-five percent of the shares subject to each stock option grant will vest on the first anniversary of the commencement date. vesting, and the remaining seventy-five percent of the shares subject to such stock option grant will vest in equal monthly installments thereafter (so that each option grant will vest 100% on the fourth anniversary of the respective vesting start date of each stock option grant). Subject to the beneficiary’s continuous service up to each such relevant date, twenty-five percent of each RSU award will vest in equal annual installments over a four-year period commencing on the first anniversary of the vesting start date ( resulting in each RSU award being 100% vested on the fourth anniversary of its respective vesting start date). In addition, each stock option and RSU grant may be subject to acceleration of vesting upon certain qualifying termination events in accordance with the terms and conditions set forth in the recipient’s offer letter with StandardBioTools.
About Standard BioTools Inc.
Standard BioTools, formerly known as Fluidigm, is driven by a bold vision – unleash tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop drugs faster and better. As a leading solutions provider, the company delivers reliable, reproducible insights into health and disease using its proprietary mass cytometry and microfluidics technologies that help turn scientific discoveries into better outcomes. for patients. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more about standardbiotools.comor join us on Twitter, Facebook, LinkedInand Youtube.
Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, and CyTOF are trademarks and/or registered trademarks of Standard BioTools or its affiliates in the United States and/or other countries. All other trademarks are the exclusive property of their respective owners. BioTools standard products are provided for research purposes only. Not for use in diagnostic procedures.
contacts:Media:Mark SpearmanFluidigm Corporation650 243 6621[email protected]
Investors:Peter DeNardo415 389 6400[email protected]
Source: Standard BioTools Inc.